Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Whole-Body Irradiation × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 26 Lymphoid 19 Myeloid 15 Plasma cell 13 Classical hematology 11 Genitourinary 4 Dermatologic 3 Sarcoma 2 Other neoplasm 2 Thoracic 1 Gynecologic 1 CNS 1

Conditions

Lung Neoplasms 1

Interventions

pembrolizumab 120 Carboplatin 112 Pemetrexed 73 Cisplatin 70 Nivolumab 67 Paclitaxel 58 Docetaxel 57 Radiotherapy 41 Erlotinib Hydrochloride 41 Gemcitabine 34 Etoposide 34 atezolizumab 30 osimertinib 29 Cetuximab 26 Ipilimumab 24 Bevacizumab 24 Radiosurgery 22 durvalumab 21 Cyclophosphamide 19 Drug Therapy 18 130-nm albumin-bound paclitaxel 16 avelumab 14 Taxes 14 Gefitinib 14 Albumin-Bound Paclitaxel 14 Irinotecan 13 Injections 13 Radiation 11 fludarabine 10 cemiplimab 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06110572 2024-06-20

TESSERACT

Vanderbilt-Ingram Cancer Center

Phase 1/2 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡